Cargando…
ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected more than 1900 humans, since 2012. The syndrome ranges from asymptomatic and mild cases to severe pneumonia and death. The virus is believed to be circulating in dromedary camels without notable symptoms since the 1980s. Theref...
Autores principales: | Alharbi, Naif Khalaf, Padron-Regalado, Eriko, Thompson, Craig P., Kupke, Alexandra, Wells, Daniel, Sloan, Megan A., Grehan, Keith, Temperton, Nigel, Lambe, Teresa, Warimwe, George, Becker, Stephan, Hill, Adrian V.S., Gilbert, Sarah C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516308/ https://www.ncbi.nlm.nih.gov/pubmed/28579232 http://dx.doi.org/10.1016/j.vaccine.2017.05.032 |
Ejemplares similares
-
Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels
por: Alharbi, Naif Khalaf, et al.
Publicado: (2019) -
Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines
por: Kandeel, Mahmoud, et al.
Publicado: (2023) -
Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021) -
A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2020) -
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial
por: Bosaeed, Mohammad, et al.
Publicado: (2022)